Vor Biopharma Inc.
VOR Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 26, 2026
$18.33
KIRA · Stoqly’s AI analyst, in plain words
- Vor Biopharma Inc. lost $696M in fiscal 2025.
- Free cash flow was −$144M in fiscal 2025, — of revenue.
- Vor Biopharma Inc. returned $0.0M to shareholders in fiscal 2025. The diluted share count rose 187.3%.
Market cap
$995M
P/E
0.1x
Revenue
—
Net income
−$696M
Free cash flow
−$144M
Operating margin
—
Vor Biopharma Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$696M
No. It lost money last year.
How is the share priced?
0.1x
One share costs 0.1 times its yearly profit per share.
What Vor Biopharma Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 30, 2026
- Legal name
- Vor Biopharma Inc.
- CIK
- 0001817229
Vor Biopharma Inc. · VOR
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$68.9M | −$92.1M | −$118M | −$117M | −$696M |
| Diluted EPS | −$2.10 | −$2.33 | −$1.75 | −$34.03 | −$70.50 |
| Cash | |||||
| Cash from operations | −$69.1M | −$85.1M | −$100M | −$99.7M | −$143M |
| Capital expenditure | $3.9M | $8.5M | $1.1M | $0.2M | $0.9M |
| Free cash flow | −$73.0M | −$93.6M | −$101M | −$99.9M | −$144M |
| Dividends paid | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Share count change | 15,544.9% | 18.3% | 69.9% | −94.9% | 187.3% |
| Debt and strength | |||||
| Cash and short-term investments | $207M | $230M | $137M | $91.9M | $455M |
| Shareholders' equity | $216M | $251M | $151M | $96.7M | −$164M |
| Current ratio | 21.1x | 18.1x | 9.0x | 5.2x | 18.2x |
| Returns and quality | |||||
| Return on equity | −87.7% | −39.5% | −58.7% | −94.5% | — |
| Return on tangible equity | −32.4% | −36.7% | −78.2% | −120.9% | — |
| Altman Z'' | 10.5 | 5.8 | −2.4 | −10.4 | −7.6 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$59.8M
3 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Vor Biopharma Inc. · VOR
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $18.33 a share, the company is worth $995M: 0.1 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001817229). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.